2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Melanoma
22
Sarcoma
8
Breast Neoplasms
5
Carcinoma, Merkel Cell
4
Triple Negative Breast Neoplasms
3
Neoplasm Metastasis
3
Carcinoma, Squamous Cell
3
Pancreatic Neoplasms
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Carcinoma, Basal Cell
2
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sezary Syndrome
1
Sarcoma, Kaposi
1
Recurrence
1
Rectal Neoplasms
1
Pleural Effusion, Malignant
1
Peritoneal Neoplasms
1
Paget Disease, Extramammary
1
Neurofibromatosis 1
1
Neurofibromatoses
1
Neurofibroma
1
Muir-Torre Syndrome
1
Microcystic adnexal carcinoma
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Interventions
Hyperthermic Intraperitoneal Chemotherapy
28
Paclitaxel
24
Cisplatin
23
Oxaliplatin
18
Cytoreduction Surgical Procedures
17
Carboplatin
17
Fluorouracil
14
Bevacizumab
10
Mitomycin
9
Leucovorin
9
Doxorubicin
9
Docetaxel
6
Gemcitabine
5
130-nm albumin-bound paclitaxel
5
Surgical Procedures, Operative
4
Neoadjuvant Therapy
4
Blood Specimen Collection
4
Albumin-Bound Paclitaxel
4
sodium thiosulfate
3
liposomal doxorubicin
3
catumaxomab
3
Taxes
3
Laparoscopy
3
Drug Therapy
3
Chemotherapy, Adjuvant
3
tremelimumab
2
relacorilant
2
pembrolizumab
2
olaparib
2
nintedanib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Peritoneal Neoplasms
×
talimogene laherparepvec
×
Clear all
NCT03663712
2024-11-20
TEMPO
Duke University
Phase 1
Completed
28 enrolled
10 charts